Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 12/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350478 | 0.80 | PDE10A (0.45) | PDE10ALMNAKDM4EMAPTHTR2C | |
| SCHEMBL12068237 | 0.80 | PDE10A (0.54) | PDE10ALMNAKDM4EMAPTCYP3A4 | |
| SCHEMBL605923 | 0.79 | PDE10A (0.50) | PDE10ALMNAKDM4EMAPTCYP3A4 | |
| SCHEMBL2546975 | 0.79 | CCR1 (0.50) | PDE10ALMNAKDM4EMAPTCYP3A4 | |
| SCHEMBL4952115 | 0.78 | PDE10A (0.47) | PDE10ALMNAKDM4EMAPTCYP3A4 | |
| SCHEMBL10309409 | 0.78 | PDE10A (0.59) | PDE10ALMNAKDM4EMAPTCYP3A4 | |
| SCHEMBL10345238 | 0.78 | PDE10A (0.72) | PDE10ALMNAKDM4EMAPTTLR7 | |
| Ammonia Solution, Strong SCHEMBL17583545 | 0.78 | PDE10A (0.49) | PDE10ALMNAKDM4EMAPTCYP3A4 | |
| Bromide SCHEMBL13822734 | 0.77 | PDE10A (0.48) | PDE10ALMNAKDM4EMAPTCYP3A4 | |
| SCHEMBL15033539 | 0.77 | PDE10A (0.48) | PDE10ALMNAKDM4EMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050208515-A1 | Method of DNA shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process | DIVERSA CORPORATION | 2005-09-22 | — | — | US | claimed |
| US-20030113759-A1 | Method of DNA shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process | SHORT JAY M (US) | 2003-06-19 | — | — | US | claimed |
| US-6440668-B1 | Method of DNA shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process | DIVERSA CORPORATION | 2002-08-27 | — | — | US | claimed |
| US-20020028443-A1 | METHOD OF DNA SHUFFLING WITH POLYNUCLEOTIDES PRODUCED BY BLOCKING OR INTERRUPTING A SYNTHESIS OR AMPLIFICATION PROCESS | DIVERSA CORPORATION | 2002-03-07 | — | — | US | claimed |
| US-5965408-A | Method of DNA reassembly by interrupting synthesis | DIVERSA CORPORATION (US) | 1999-10-12 | — | — | US | claimed |
| CN-113789316-A | Phytases, nucleic acids encoding them and methods of making and using them | 巴斯夫酶有限责任公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-106222185-B | Glucanases, nucleic acids encoding them and methods of making and using them | 维莱尼姆公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-104450754-B | Phytases, nucleic acids encoding them and methods of making and using them | 巴斯夫酶有限责任公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-110577945-A | xylanases, nucleic acids encoding them, and methods for making and using them | 维莱尼姆公司 | 2019-12-17 | — | — | CN | disclosed |
| US-10428340-B2 | Phytases, nucleic acids encoding them and methods for making and using them | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-01 | — | — | US | disclosed |
| US-10329549-B2 | Glucanases, nucleic acids encoding them and methods for making and using them | BP CORPORATION NORTH AMERICA INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190127712-A1 | Phytases, Nucleic Acids Encoding Them and Methods for Making and Using Them | SYNGENTA PARTICIPATIONS AG (CH) | 2019-05-02 | — | — | US | disclosed |
| US-20020012974-A1 | Genetic engineered nucleic acid promoter | VERENIUM CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-20020006620-A1 | Morphatides: novel shape and structure libraries | INVITROGEN CORPORATION | 2002-01-17 | — | — | US | disclosed |
| WO-2001048175-A2 | METHODS FOR PRODUCING ENANTIOMERICALLY PURE α-SUBSTITUTED CARBOXYLIC ACIDS | DIVERSA CORPORATION (US) | 2001-07-05 | — | — | WO | disclosed |
| US-6238884-B1 | SUBJECTING POLYNUCLEOTIDES TO SIMULTANEOUS MUTAGENESIS BY AMPLIFYING USING DEGENERATE OLIGONUCLEOTIDES, THEN SUBJECTING PROGENY POLYNUCLEOTIDES TO END SELECTION-BASED SCREENING AND ENRICHMENT PROCESS TO CREATE LIGATION-COMPATIBLE ENDS | DIVERSA CORPORATION | 2001-05-29 | — | — | US | disclosed |
| US-6171820-B1 | Saturation mutagenesis in directed evolution | DIVERSA CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-0954600-A2 | MORPHATIDES: NOVEL SHAPE AND STRUCTURE LIBRARIES | Morphagen (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5965408-A | Method of DNA reassembly by interrupting synthesis | DIVERSA CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1998016661-A2 | MORPHATIDES: NOVEL SHAPE AND STRUCTURE LIBRARIES | MORPHAGEN (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020012974-A1 | Genetic engineered nucleic acid promoter | RNGTT, ASPH, ALKBH3 | PDE10A 4357/4885LMNA 1933/4885KDM4E 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.